Sun Pharma to get an exclusive right to commercialize Nidlegy (developed by Philogen), a new anti-cancer biopharmaceutical drug for skin cancers in the territories of EU, Australia & New Zealand along with being responsible for commercialization activities
Philogen will hold IP rights for Nidlegy in other territories & indications excl. skin cancer. Post-commercialization costs will be split equally b/w 2 companies in a ratio (50:50)
Philogen intends to complete pivotal clinical studies for Nidlegy in the EU & seek marketing authorization from the regulatory authorities, will also be involved in the manufacture of commercial supplies. Nidlegy is being studied in the P-III trials for melanoma & non-melanoma skin cancers
Ref: PR Newswire | Image: Sun Pharma
Related News:- Sun Pharmaceutical’ Sezaby Receives the US FDA’s Approval for the Treatment of Neonatal Seizures
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
